PSORCON E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PSORCON E (PSORCON E).
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Primarily hepatic via CYP3A4; undergoes phase II conjugation. |
| Excretion | Primarily hepatic metabolism followed by renal excretion of metabolites; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for <2%. |
| Half-life | Terminal elimination half-life is approximately 6-8 hours for the parent compound; active metabolites may have half-lives up to 12 hours. Clinically, this supports twice-daily dosing. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Volume of distribution is approximately 1.2-1.5 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Topical bioavailability is less than 1% through intact skin; systemic absorption increases with occlusive dressings, inflamed skin, or high potency formulations. Not available orally or parenterally. |
| Onset of Action | Topical application: Onset of anti-inflammatory effect within 1-2 hours; peak vasoconstriction observed at 4-6 hours. |
| Duration of Action | Duration of action is 12-24 hours for anti-inflammatory effect; clinical improvement may persist for several days after discontinuation. Twice-daily dosing is recommended for sustained effect. |
| Molecular Weight | 490.43 |
Topical: Apply a thin film to affected skin areas twice daily. No systemic dosing applicable.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment as systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for hepatic impairment as systemic absorption is minimal. |
| Pediatric use | Apply a thin film to affected skin areas twice daily; use lowest effective potency for shortest duration due to increased risk of systemic absorption. |
| Geriatric use | Apply a thin film to affected skin areas twice daily; use caution due to thinner skin and increased potential for systemic effects; limit treatment duration. |
| 1st trimester | Topical corticosteroids like diflorasone diacetate are pregnancy category C. Systemic absorption is low with topical use, but prolonged or extensive application should be avoided. Animal studies have shown teratogenicity with systemic corticosteroids. Use only if potential benefit justifies fetal risk. |
| 2nd trimester | Same as first trimester. Use with caution; avoid large areas, prolonged use, or occlusive dressings. |
| 3rd trimester | Same as first and second trimesters. Third trimester use may increase risk of low birth weight if used excessively. |
Clinical note
Comprehensive clinical and safety monograph for PSORCON E (PSORCON E).
| Placental transfer | Corticosteroids, including diflorasone diacetate, can cross the placenta. Transplacental transfer is minimal with topical use but increases with extent of application, occlusive dressings, and damaged skin. |
| Breastfeeding | Topical diflorasone diacetate is excreted in breast milk in small amounts. However, with topical application, systemic absorption is minimal. Caution is advised when applied to large areas, under occlusion, or on broken skin. Not expected to cause adverse effects in nursing infants when used sparingly. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to diflorasone diacetate or any component of the formulation.Untreated bacterial, fungal, viral, or parasitic skin infections.Perioral dermatitis.Rosacea.Application to face, groin, or axillae (high potency formulations).
| Precautions | Reversible HPA axis suppression with prolonged use or large doses, Topical use may cause systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria, Avoid occlusive dressings unless directed, Use caution in pediatric patients due to increased absorption, Local adverse reactions: skin atrophy, striae, telangiectasias, purpura, hypertrichosis, acneiform eruptions, hypopigmentation, allergic contact dermatitis |
| Food/Dietary | No specific food interactions known. Maintain a balanced diet; no restrictions required. |
Loading safety data…
| Lactation Rating | L2 (Safer) - limited data but likely safe with short-term, small area use. |
| Teratogenic Risk | Topical corticosteroids like PSORCON E (diflorasone diacetate) are generally considered low risk for teratogenicity when used at recommended doses. However, prolonged or high-dose use during the first trimester may be associated with a small increased risk of orofacial clefts. During the second and third trimesters, high systemic exposure may cause fetal adrenal suppression and growth retardation. Avoid use over large body surface areas or occlusive dressings. |
| Fetal Monitoring | Monitor maternal adrenal function if prolonged or high-dose use is necessary. Fetal monitoring with ultrasound for growth parameters if repeated high-potency corticosteroid use occurs. |
| Fertility Effects | In animal studies, high systemic doses of corticosteroids may impair fertility. However, topical use at recommended doses is unlikely to affect human fertility. |
| Clinical Pearls | PSORCON E (diflorasone diacetate) is a high-potency topical corticosteroid. Limit use to 2 weeks continuous; avoid occlusion unless supervised. Do not use on face, groin, or axillae due to risk of atrophy. Monitor for HPA axis suppression with large areas or prolonged use. Can cause tachyphylaxis. |
| Patient Advice | Apply a thin layer to affected areas only, usually once or twice daily as directed. · Do not bandage or cover the area unless instructed by your doctor. · Avoid contact with eyes, mouth, and broken skin. · Do not use more than prescribed or for longer than recommended. · Inform your doctor if condition worsens or does not improve within 2 weeks. · Do not use on face, underarms, or groin unless specifically directed. · Wash hands after application unless treating hands. |